Dr. Kathryn Nevel talks with Dr. Ingo Mellinghoff about how vorasidenib improved progression-free survival in patients with Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas.

Read the related article in The New England Journal of Medicine.

Visit NPUb.org/Podcast for associated article links.